Regeneron’s new biologic boosts small molecule binding

Regeneron has expanded its suite of drug discovery technologies by developing a new type of biologic capable of binding small molecules better than conventional antibodies.

The company has been seeking new technologies -- such as nucleic acid therapies and cell therapies -- to take on targets for which its antibody platform isn’t the right fit (see “Independent Biotechs Bulk Up Their Platforms with More Modalities”). ...